Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2025-04-06 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
监事会关于公司2025年度向特定对象发行A股股票相关事项的书面审核意见
Capital/Financing Update Classification · 95% confidence The document is a written supervisory board opinion regarding the company's planned issuance of A shares to specific investors in 2025. It references relevant laws and regulations governing securities issuance and confirms the fairness, legality, and feasibility of the issuance plan. The document is a formal approval or opinion on a capital raising activity rather than the actual issuance announcement or detailed financial report. It does not contain financial statements or earnings data but focuses on the issuance plan and regulatory compliance. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2025-04-06 Chinese
2025年度向特定对象发行A股股票方案论证分析报告（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed report titled '2025 年度向特定对象发行 A 股股票 方案论证分析报告（修订稿）' by Haisco Pharmaceutical Group Co., Ltd. It discusses the company's plan to issue A shares to specific investors, including the background, purpose, legal compliance, pricing, and impact on financial indicators. The content includes extensive analysis of the issuance plan, regulatory compliance references (such as the Securities Law, Company Law, and Registration Management Measures), and detailed financial impact assessments. This is a comprehensive analysis report supporting a capital raising activity through a targeted share issuance. It is not a simple announcement or a brief summary but a full analytical report on the capital issuance plan. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2025-04-06 Chinese
关于2025年度向特定对象发行A股股票预案（修订稿）披露的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (555 characters) regarding a company's plan to issue A shares to specific investors, described as a "预案（修订稿）" (proposal or plan revision). It mentions board and supervisory meetings approving the plan and references further details available on an external website. The text explicitly states that the announcement does not represent approval by regulatory authorities and that the issuance is subject to shareholder and regulatory approvals. There are no financial statements or detailed financial data included. The document is an update on a capital raising plan, specifically a share issuance proposal, but it is not the full detailed report or prospectus itself. Given the short length and nature of the content, this fits best under "Capital/Financing Update (CAP)" rather than a full report or regulatory filing. Therefore, the classification is CAP with high confidence.
2025-04-06 Chinese
关于暂不召开股东大会审议2025年度向特定对象发行股票相关事项的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (503 characters) from a company about the decision to temporarily not hold a shareholders' meeting to review a specific stock issuance matter. It references a board meeting and states that the shareholders' meeting will be scheduled later. There is no detailed financial data or report content, only an announcement about the meeting status related to a capital issuance. This fits the category of Capital/Financing Update (CAP) because it concerns issuance of shares to specific parties and related meeting arrangements, rather than the actual issuance or a full report. The document is not a report publication announcement or regulatory filing since it contains substantive update on financing plans and meeting decisions. Confidence is high due to clear context and content.
2025-04-06 Chinese
简式权益变动报告书
Major Shareholding Notification Classification · 95% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details changes in shareholding relationships among key shareholders, specifically the termination of a concerted action agreement among three shareholders, resulting in changes in the calculation of their combined shareholdings but not in the actual number of shares held by each individual. The document includes detailed tables of shareholdings before and after the change, legal references to Chinese securities laws, and declarations of compliance and accuracy. There is no indication of financial statements, earnings data, or management discussion of financial results. The document is a formal disclosure of changes in significant share ownership and control relationships, fitting the definition of a Major Shareholding Notification (MRQ). The length (7041 characters) and content confirm it is a full report, not just an announcement or certification. Therefore, the correct classification is MRQ with high confidence.
2025-03-30 Chinese
关于相关股东解除一致行动关系暨控股股东、实际控制人变更的提示性公告
Regulatory Filings Classification · 95% confidence The document is an official announcement regarding the change in the company's controlling shareholders and the termination of a shareholder agreement among key shareholders. It details the change in actual control from three individuals to one, provides shareholding details before and after the change, and includes legal opinions confirming the validity of the change. There are no financial statements, earnings data, or detailed management discussions. The document is a regulatory announcement about shareholder structure and control changes, not a full report or financial filing. It fits best under the category of Regulatory Filings (RNS) as it is a compliance disclosure about shareholder and control changes without being a formal management or board announcement or a capital financing update.
2025-03-30 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.